VistaGen Therapeutics Company Presentation

www.vistagen.com 15 • Recent FDA consensus that design of pivotal Phase 3 clinical studies will mirror highly statistically significant (p=0.002) Phase 2 public speaking study ƒ Single, laboratory-simulated, anxiety-provoking public speaking challenge ƒ Single dose, 3.2 P g ƒ Primary efficacy endpoint assessed using Subjective Units of Distress Scale (SUDS) • 15 sites in North America • Target enrollment (completed subjects), 182 PH94B North American Pivotal Phase 3 SAD Study Summary: Acute Treatment of Anxiety for Adults with Social Anxiety Disorder Principal Investigator: Dr. Michael Liebowitz, Columbia University, New York